Immunogenic Memapsin 2 and $\beta$-Secretase Peptides For Use In The Treatment of Alzheimer’s Disease and Memapsin 2/$\beta$-Secretase Disorders

Technology:
2008-012

Inventors:
Dr. Jordan Tang and Dr. Wanpin Chang

Invention Description:
Scientific investigation during the last two decades has substantiated a prominent role for brain amyloid-beta (A $\beta$) in the pathogenesis of Alzheimer’s disease. Memapsin 2 initiates cleavage of amyloid precursor protein (APP) leading to the production of A $\beta$ and the onset of Alzheimer’s Disease. The OMRF technology provides methods, compositions, unit dosages, and immunogenic compositions comprising memapsin 2 or $\beta$-secretase peptides for therapeutic and prophylactic uses.

Market Application:
Alzheimer’s disease inflicts 18 million people worldwide, and this number is projected to be about 24 million by 2025. The annual direct and indirect costs of caring for someone with Alzheimer’s disease is $100 billion.

Features, Benefits, and Advantages:
OMRF Invention provides an immunological prospective for therapeutic development in the fight against Alzheimer’s.

Intellectual Property:
US Patent 7,989,597 and foreign counterparts

Stage of Development
Proof of concept studies completed. We are currently seeking industry partners to collaborate with us (in the form of research collaboration, licensing etc.) to develop and commercialize this technology.